Total trials
2,042
Active
323
Phase 3
60
Total enrollment
2,391,724
Pipeline matrix
Showing 40 of 132 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Saline | — | — | — | — | 9 | ||
| Fentanyl/Hydromorphone | — | — | — | — | 3 | ||
| Chloroprocaine | — | — | — | — | — | 2 | |
| Buprenorphine | — | — | — | — | 2 | ||
| Propofol | — | — | — | — | 4 | ||
| Methadone | — | — | — | — | 3 | ||
| Hyperbaric oxygen | — | — | — | — | 2 | ||
| Mepivacaine | — | — | — | — | — | 2 | |
| Lidocaine 2% | — | — | — | — | — | 1 | |
| Nutrition Ecosystem pathway | — | — | — | — | — | 1 | |
| Artemether-lumefantrine | — | — | — | — | — | 1 | |
| Quadratus Lumborum with 1.5% Lidocaine | — | — | — | — | — | 1 | |
| Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL | — | — | — | — | — | 1 | |
| Normal Saline | — | — | — | — | — | 1 | |
| Cabotegravir | — | — | — | — | — | 1 | |
| Cabotegravir Pill | — | — | — | — | — | 1 | |
| Buprenorphine Pill | — | — | — | — | — | 1 | |
| Tirzepatide | — | — | — | — | — | 1 | |
| Tirzepatide Placebo | — | — | — | — | — | 1 | |
| HA Chemotherapy | — | — | — | — | — | 1 | |
| transdermal nicotine replacement therapy | — | — | — | — | — | 1 | |
| ESP Block with Bupivacaine | — | — | — | — | — | 1 | |
| ESP Block with Bupivacaine + Liposomal Bupivacaine | — | — | — | — | — | 1 | |
| Methadone hydrochloride | — | — | — | — | — | 1 | |
| Sofosbuvir / Velpatasvir Oral Tablet [Epclusa] | — | — | — | — | — | 1 | |
| Liposomal Bupivacaine with Bupivacaine | — | — | — | — | — | 1 | |
| Oxymetazoline 0.1% | — | — | — | — | — | 1 | |
| Brimonidine 0.025% | — | — | — | — | — | 1 | |
| Pre-Exposure Prophylaxis | — | — | — | — | — | 1 | |
| Inclisiran | — | — | — | — | — | 1 | |
| Ferric derisomaltose | — | — | — | — | — | 1 | |
| Lenacapavir long-acting | — | — | — | — | — | 1 | |
| Respiratory Syncytial Virus (RSV) Preventive Monoclonal Antibody | — | — | — | — | — | 1 | |
| Atorvastatin 40 Mg Oral | — | — | — | — | — | 1 | |
| Dexamethasone | — | — | — | 8 | |||
| Abatacept | — | — | — | — | 3 | ||
| Tocilizumab | — | — | — | — | 2 | ||
| Rosuvastatin 20 Mg Oral | — | — | — | — | — | 1 | |
| Colchicine 0.5 MG Oral Tablet Once Daily | — | — | — | — | — | 1 | |
| TNFi (Tumor Necrosis Factor inhibitor) medication | — | — | — | — | — | 1 |
92 more active programs hidden
Next readouts
- 2024-10-17
- 2025-09-16
- 2025-11-03
- 2025-11-18
- 2026-02-20
- 2026-05
- 2026-06-30
- 2026-06-30
- 2026-06-30
- 2026-07-01
Top conditions
- Obesity53
- Breast Cancer49
- Heart Failure43
- Prostate Cancer40
- Hypertension39
- Depression37
- Brain and Central Nervous System Tumors30
- Pain26
Frequently asked questions about Duke University
- How many clinical trials does Duke University have on ClinicalTrials.gov?
- Duke University is listed as the lead sponsor on 2,042 clinical trials in ClinicalTrials.gov, 323 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Duke University's trials are in Phase 3?
- 60 of Duke University's trials are in Phase 3, spread across 132 active drug programs.
- What therapeutic areas does Duke University focus on?
- Duke University's most-studied conditions on ClinicalTrials.gov are Obesity, Breast Cancer, Heart Failure, Prostate Cancer, Hypertension.
- When are Duke University's next clinical trial readouts?
- Duke University has 10 upcoming primary-completion readouts tracked here; the soonest is “Genentech Xenon MRI Idiopathic Pulmonary Fibrosis”, expected around 2024-10-17.